dbACP: A Comprehensive Database of Anti-Cancer Peptides

37 result(s) have been found!

Accession Name Sequence Source/Organism Mechanism Assay Type Cell Line Cancer Type Activity
dbacp00774 A12L KWKSFLKTFKSLKKTVLHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-375 Skin cancer IC50 : 4.3 µMo/L
dbacp00782 A12L/A20L KWKSFLKTFKSLKKTVLHTLLKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-375 Skin cancer IC50 : 8.7 µMo/L
dbacp00790 A12L/A20L/A23L KWKSFLKTFKSLKKTVLHTLLKLISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-375 Skin cancer IC50 : 7.2 µMo/L
dbacp00798 A20L KWKSFLKTFKSAKKTVLHTLLKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-375 Skin cancer IC50 : 6.5 µMo/L
dbacp03571 L17A KWKSFLKTFKSAKKTVAHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-375 Skin cancer IC50 : > 83.6 µMo/L
dbacp03579 L17A/L21A KWKSFLKTFKSAKKTVAHTAAKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-375 Skin cancer IC50 : > 83.6 µMo/L
dbacp03590 L21A KWKSFLKTFKSAKKTVAHTAAKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-375 Skin cancer IC50 : 59.8 µMo/L
dbacp03614 L6A KWKSFAKTFKSAKKTVLHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-375 Skin cancer IC50 : 58.7 µMo/L
dbacp03622 L6A/L17A KWKSFAKTFKSAKKTVAHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-375 Skin cancer IC50 : >83.6 µMo/L
dbacp05022 Peptide P KWKSFLKTFKSAKKTVLHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-375 Skin cancer IC50 : 17.8 µMo/L
dbacp05043 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay A-375 Skin cancer 86 ± 0.57% cell viability at 10 µM
dbacp05044 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay A-375 Skin cancer 63.8 ± 0.8% cell viability at 20 µM
dbacp05045 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay A-375 Skin cancer 47.5 ± 1.66% cell viability at 40 µM
dbacp05046 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay A-375 Skin cancer 26.9 ± 0.5% cell viability at 60 µM
dbacp05047 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay A-375 Skin cancer 6.5 ± 1.07% cell viability at 80 µM
dbacp06802 A11 EYVQTVKSSKG Annexin A1 Targeting PD-L3 Biotin Pull Down assay A-375 Skin Cancer Not Available
dbacp07008 ST101 vaeareelerlearlgqargelkkwkmrrnqfwlklqr Synthetic Prevents C/EBPβ dimerization, induces degradation Annexin V/ PI staining assay A-375 Skin Cancer mean EC50 value of 2.1 ± 0.4 μmol/L
dbacp07360 N-Ter-TAT RDVFTKGYGFGL-GRK(Dansylglycine)KRRQRRRPQ Synthetic Mitochondrial targeting, VDAC1-HKII dissociation MTT assay A-375 Skin Cancer IC50 > 50.0 μM
dbacp07361 Pal-N-Ter-TAT Pal-RDVFTKGYGFGL-GRK(Dansylglycine)KRRQRRRPQ Analogue of N-terminal fragment of the VDAC1 protein Mitochondrial targeting, VDAC1-HKII dissociation MTT assay A-375 Skin Cancer IC50 = 36.67(Supplementary material)/15.2 ± 0.7 μM(Published paper)
dbacp07364 pFL-N-Ter-TAT FPWWWPFL-RDVFTKGYGFGL-GRK(Dansylglycine)KRRQRRRPQ Analogue of N-terminal fragment of the VDAC1 protein Mitochondrial targeting, VDAC1-HKII dissociation MTT assay A-375 Skin Cancer IC50 = 11.1 ± 0.1 μM
dbacp07465 ΔM4 NFFKRIRRAWKRIWKWIYSA Synthetic Membrane disruption triggers mitochondrial apoptosis Not Available A-375 Skin Cancer IC50 = 9.31 μM
dbacp07578 R-DIM-P-LF11 FQWQRNIRKVRPRVKRINRQWQF Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay A-375 Skin Cancer LC50 = 125.0 ± 16.8 μM
dbacp07581 R-DIM-P-LF11-322 PFWRIRIRRPRRIRIRWFP Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay A-375 Skin Cancer LC50 = 4.2 ± 0.2 μM
dbacp07584 DIM-LF11-322 PFWRIRIRRPFWRIRIRR Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay A-375 Skin Cancer LC50 = 6.3 ± 0.3 μM
dbacp07587 R-DIM-P-LF11-215 FWRIRIRRPRRIRIRWF Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay A-375 Skin Cancer LC50 = 2.7 ± 0.9 μM
dbacp07590 R-DIM-P-LF11-334 PWRIRIRRPRRIRIWP Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay A-375 Skin Cancer LC50 = 6.6 ± 0.3 μM
dbacp07593 R-DIM-LF11-334-LF11-334 PWRIRIRRRRIRIRWPPWRIRIRR Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay A-375 Skin Cancer LC50 < 1 ± 0.1 μM
dbacp07596 DIM-LF11-339 RRWFWRRRRWFWRR Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay A-375 Skin Cancer LC50 = 4.8 ± 0.4 μM
dbacp07648 AP1-Z1 FLFSLIPHAISGLISAFK AcrAP1 from the venom of the Arabian scorpion Charge–hydrophobicity balance drives apoptosis MTT assay A-375 Skin Cancer IC50 = 9.478 μM
dbacp07651 AP1-Z5a FLFKLIPKAIKGLIKAFK Mutant of APR-Z1 Charge–hydrophobicity balance drives apoptosis MTT assay A-375 Skin Cancer Graph Figure 2B
dbacp07654 AP1-Z5b FLFKLIKHAIKGLIKAFK Mutant of APR-Z1 Charge–hydrophobicity balance drives apoptosis MTT assay A-375 Skin Cancer IC50 = 2.607 μM
dbacp07657 AP1-Z3a FLFSLIKHAIKGLISAFK Mutant of APR-Z1 Charge–hydrophobicity balance drives apoptosis MTT assay A-375 Skin Cancer Graph Figure 2B
dbacp07660 AP1-Z3b FLFSLIKHAISKLISAFK Mutant of APR-Z1 Charge–hydrophobicity balance drives apoptosis MTT assay A-375 Skin Cancer Graph Figure 2B
dbacp07663 AP1-Z7 FLFKLIKKAIKKLIKAFK Mutant of APR-Z1 Charge–hydrophobicity balance drives apoptosis MTT assay A-375 Skin Cancer Graph Figure 2B
dbacp07666 AP1-Z9 FLFKLIKKKIKKLIKKFK Mutant of APR-Z1 Charge–hydrophobicity balance drives apoptosis MTT assay A-375 Skin Cancer Graph Figure 2B
dbacp07879 Nubein6.8 LKCNQLIPPFWKTCPKGKNLCYKMTMRAAPMVPVKRGCIDVCPKSSLLIKYMCCNTDKCN Naja nubiae DNA damage and apoptosis induction MTT assay A-375 Skin Cancer EC50 = 0.54 ± 0.04 μM
dbacp08167 Bmattacin2 Not Available silkworm Bombyx mori Not Available MTS assay A-375 Skin Cancer IC50 = 5.23 μM